{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:46:33Z","timestamp":1795088793690,"version":"4.10.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) is a potentially life-threatening complication of haematopoietic cell transplantation (HCT) conditioning. The DEFIFrance post-marketing registry study evaluated effectiveness and safety in patients who received defibrotide. It collected retrospective\/prospective patient data from 53 French HCT centres from July 2014 to March 2020. Primary endpoints were survival and complete response (CR; total serum bilirubin &lt;2\u2009mg\/dL, multiorgan failure resolution) at Day 100 post-HCT among patients with severe\/very severe VOD\/SOS. A secondary endpoint was evaluation of treatment-emergent serious adverse events (TESAEs) of interest. Of 798 patients analysed, 251 and 81 received defibrotide treatment for severe\/very severe VOD\/SOS and mild\/moderate VOD\/SOS post-HCT, respectively; 381 received defibrotide for VOD\/SOS prophylaxis. In patients with severe\/very severe VOD\/SOS post-HCT, Kaplan\u2013Meier\u2013estimated CR at Day 100 was 74% (95% confidence interval [CI]: 66%, 81%). At Day 100, 137\/251 (55%) were alive and in CR. Kaplan\u2013Meier\u2013estimated Day 100 post-HCT survival was 61% (95% CI: 55%, 67%) in patients with severe\/very severe VOD\/SOS. TESAEs of interest occurred in 29% of these patients; VOD\/SOS-related mortality at 12 months was 15%. DEFIFrance represents the largest collection of real-world data on post-registration defibrotide use, supporting the real-world utility of defibrotide for patients with severe\/very severe VOD\/SOS post-HCT.<\/jats:p>","DOI":"10.1038\/s41409-022-01900-6","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:03:43Z","timestamp":1671797023000},"page":"367-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance Registry Study"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Detrait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Izadifar-Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Jubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-1559","authenticated-orcid":false,"given":"Delphine","family":"Lebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3136-6270","authenticated-orcid":false,"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobby","family":"Asubonteng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenna\u00eblle","family":"Guindeuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"1900_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489.","journal-title":"Front Immunol"},{"key":"1900_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2019.10.024","volume":"26","author":"C Lewis","year":"2020","unstructured":"Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, et al. Incidence, predictors, and outcomes of veno-occlusive disease\/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:529\u201339.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4:332\u201346.","journal-title":"J Clin Exp Hepatol"},{"key":"1900_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14740338.2012.749855","volume":"12","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12:123\u201336.","journal-title":"Expert Opin Drug Saf"},{"key":"1900_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.16621","volume":"190","author":"GC Hildebrandt","year":"2020","unstructured":"Hildebrandt GC, Chao N. Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation. Br J Haematol. 2020;190:508\u201319.","journal-title":"Br J Haematol"},{"key":"1900_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365.","journal-title":"Blood."},{"key":"1900_CR9","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","volume":"22","author":"S Corbacioglu","year":"2016","unstructured":"Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR10","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41409-021-01265-2","volume":"56","author":"M Mohty","year":"2021","unstructured":"Mohty M, Battista ML, Blaise D, Calore E, Cesaro S, Maximova N, et al. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease\/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transplant. 2021;56:2454\u201363.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327.","journal-title":"Br J Haematol"},{"key":"1900_CR12","unstructured":"Defitelio. Defitelio (defibrotide sodium) injection [packet insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2016."},{"key":"1900_CR13","unstructured":"Defitelio(R) (defibrotide) for intravenous use [package insert]. Jazz Pharmaceuticals Ireland Limited; 2021."},{"key":"1900_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138\u201345.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.bbmt.2020.03.011","volume":"26","author":"S Corbacioglu","year":"2020","unstructured":"Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease\/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2020;26:1342\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant. 2016;51:403\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41409-020-00998-w","volume":"56","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, et al. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transplant. 2021;56:175\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR19","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.bbmt.2016.04.011","volume":"22","author":"C Strouse","year":"2016","unstructured":"Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2016;22:1306\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1900_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"SI Bearman","year":"1997","unstructured":"Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood. 1997;89:1501\u20136.","journal-title":"Blood."},{"key":"1900_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/sj.bmt.1705969","volume":"41","author":"L Barkholt","year":"2008","unstructured":"Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:785\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"1900_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","volume":"42","author":"S Corbacioglu","year":"2022","unstructured":"Corbacioglu S, Topaloglu O, Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno occlusive disease\/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42:465\u201376.","journal-title":"Clin Drug Investig"},{"key":"1900_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139.","journal-title":"Lancet."},{"key":"1900_CR24","unstructured":"Mohty M, Bourhis JH, Faraci M, Iori AP, Huynh A, Amber V, et al. Defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) after haematopoietic cell transplantation (HCT): Analysis of a multicentre, multinational, prospective, observational registry study (EBMT PASS). Oral presentation at: 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT); 2021; Virtual.2021."},{"key":"1900_CR25","unstructured":"ClinicalTrials.gov. Study comparing efficacy and safety of defibrotide vs best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02851407."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01900-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01900-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T06:52:59Z","timestamp":1680677579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01900-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01900-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM: has received honoraria and research funding from Jazz Pharmaceuticals. DB: has received honoraria from Jazz Pharmaceuticals. RPdL: has received honoraria from Jazz Pharmaceuticals. ML: has received honoraria from Jazz Pharmaceuticals. JHB: no competing interests. BB: no competing interests. PC: no competing interests. MD: has received research funding from Jazz Pharmaceuticals. VG: no competing interests. AH: has received honoraria from Jazz Pharmaceuticals. FILeG: no competing interests. CJ: has received honoraria from Jazz Pharmaceuticals. HL-W: no competing interests. DL: no competing interests. SM: no competing interests. C\u00a0Paillard: no competing interests. C\u00a0Pochon: no competing interests. CR: has received funding from Jazz Pharmaceuticals. FR: no competing interests. PS: no competing interests. AS: no competing interests. KA: employee of Jazz Pharmaceuticals and holds stock and\/or stock options in Jazz Pharmaceuticals. GG: employee of Jazz Pharmaceuticals and holds stock and\/or stock options in Jazz Pharmaceuticals. IY-A: has received honoraria from Jazz Pharmaceuticals. J-HD: has received honoraria from Jazz Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in compliance with the ethical principles defined in the Declaration of Helsinki and according to Good Epidemiological Practice defined by ADELF (Association Des Epid\u00e9miologistes de Langue Fran\u00e7aise\u2014Association of French-language Epidemiologists) and current legislation. Written, informed consent was obtained from the patient or the patient\u2019s legal guardian. Data from deceased patients were included if the patient did not express opposition to the collection of their data while they were alive.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}